Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

Venetoclax is a first-in-class cancer therapy that interacts with the cellular apoptotic machinery promoting apoptosis. Treatment of patients suffering chronic lymphocytic leukaemia with this BCL-2 antagonist has revealed emergence of a drug-selected BCL-2 mutation (G101V) in some patients failing t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Nat Commun
Hlavní autoři: Birkinshaw, Richard W., Gong, Jia-nan, Luo, Cindy S., Lio, Daisy, White, Christine A., Anderson, Mary Ann, Blombery, Piers, Lessene, Guillaume, Majewski, Ian J., Thijssen, Rachel, Roberts, Andrew W., Huang, David C. S., Colman, Peter M., Czabotar, Peter E.
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6547681/
https://ncbi.nlm.nih.gov/pubmed/31160589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-10363-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky